BioTime Stock Price, News & Analysis (NYSEAMERICAN:BTX)

$2.65 0.09 (3.52 %)
(As of 11/24/2017 06:33 AM ET)
Previous Close$2.65
Today's Range$2.55 - $2.65
52-Week Range$2.19 - $3.96
Volume184,119 shs
Average Volume432,707 shs
Market Capitalization$350.75 million
P/E RatioN/A
Dividend YieldN/A


BioTime logoBioTime, Inc. is a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases. Its clinical programs are based on two platform technologies: pluripotent stem cells and cell/drug delivery platform technologies. The foundation of its cell delivery platform is its HyStem cell and drug delivery matrix technology. Its clinical programs are targeting three primary sectors, aesthetics, ophthalmology and cell/drug delivery. Its facial aesthetics product, Renevia, is a potential treatment for facial lipoatrophy. It is in a pivotal clinical trial in Europe to assess its safety and efficacy in restoring normal skin contours in patients whose subcutaneous fat, or adipose tissue, has been lost due to the use of certain drugs often used to treat patients with human immune virus. OpRegen is its lead product for ophthalmological disorders. It is a suspension of retinal pigment epithelial cells that are derived from pluripotent stem cells.

Receive BTX News and Ratings via Email

Sign-up to receive the latest news and ratings for BTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
  • Previous Symbol: NYSEMKT:BTX
  • CUSIP09066L10


    Debt-to-Equity RatioN/A
    Current RatioN/A
    Quick RatioN/A


    Trailing P/E RatioN/A
    Forward P/E RatioN/A
    P/E GrowthN/A

    Sales & Book Value

    Annual SalesN/A
    Price / SalesN/A
    Cash FlowN/A
    Price / CashN/A
    Book ValueN/A
    Price / BookN/A


    Trailing EPS$0.43
    Net IncomeN/A
    Net Margins-3,209.19%
    Return on Equity-25.71%
    Return on Assets-24.61%


    Outstanding Shares126,870,000

    Frequently Asked Questions for BioTime (NYSEAMERICAN:BTX)

    What is BioTime's stock symbol?

    BioTime trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "BTX."

    How were BioTime's earnings last quarter?

    BioTime, Inc. (NYSEAMERICAN:BTX) announced its quarterly earnings results on Tuesday, August, 9th. The biotechnology company reported ($0.11) earnings per share for the quarter, beating analysts' consensus estimates of ($0.17) by $0.06. The biotechnology company had revenue of $1.27 million for the quarter, compared to analysts' expectations of $1.75 million. BioTime had a negative return on equity of 25.71% and a negative net margin of 3,209.19%. View BioTime's Earnings History.

    Where is BioTime's stock going? Where will BioTime's stock price be in 2017?

    2 equities research analysts have issued 12 month price objectives for BioTime's stock. Their forecasts range from $6.00 to $6.50. On average, they expect BioTime's share price to reach $6.25 in the next twelve months. View Analyst Ratings for BioTime.

    Are investors shorting BioTime?

    BioTime saw a decline in short interest in the month of October. As of October 31st, there was short interest totalling 6,767,992 shares, a decline of 0.9% from the October 13th total of 6,827,321 shares. Based on an average daily trading volume, of 417,019 shares, the short-interest ratio is currently 16.2 days. Currently, 5.7% of the company's stock are short sold.

    Who are some of BioTime's key competitors?

    Who are BioTime's key executives?

    BioTime's management team includes the folowing people:

    • Alfred D. Kingsley, Chairman of the Board (Age 74)
    • Aditya P. Mohanty, Co-Chief Executive Officer, Director (Age 50)
    • Michael D. West Ph.D., Co-Chief Executive Officer, Director (Age 63)
    • Russell L. Skibsted, Chief Financial Officer (Age 58)
    • Judith Segall, Vice President, Secretary (Age 61)
    • Stephana Eilene Patton Ph.D., J.D., General Counsel (Age 46)
    • Deborah J. Andrews, Independent Director (Age 59)
    • Neal C. Bradsher, Independent Director (Age 51)
    • Stephen C. Farrell CPA, Independent Director (Age 52)
    • Michael H. Mulroy, Independent Director (Age 51)

    Who owns BioTime stock?

    BioTime's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Broadwood Capital Inc. (22.64%), IndexIQ Advisors LLC (0.22%), Family Management Corp (0.15%), GSA Capital Partners LLP (0.14%), Dimensional Fund Advisors LP (0.13%) and Schwab Charles Investment Management Inc. (0.09%). Company insiders that own BioTime stock include Aditya P Mohanty, Broadwood Partners Lp, Broadwood Partners, LP, Deborah J Andrews, Michael D West and Russell Skibsted. View Institutional Ownership Trends for BioTime.

    Who sold BioTime stock? Who is selling BioTime stock?

    BioTime's stock was sold by a variety of institutional investors in the last quarter, including Schwab Charles Investment Management Inc. and Russell Investments Group Ltd.. View Insider Buying and Selling for BioTime.

    Who bought BioTime stock? Who is buying BioTime stock?

    BioTime's stock was purchased by a variety of institutional investors in the last quarter, including Broadwood Capital Inc., IndexIQ Advisors LLC, GSA Capital Partners LLP, Family Management Corp, Dimensional Fund Advisors LP and Jane Street Group LLC. Company insiders that have bought BioTime stock in the last two years include Aditya P Mohanty, Broadwood Partners Lp, Broadwood Partners, LP, Deborah J Andrews, Michael D West and Russell Skibsted. View Insider Buying and Selling for BioTime.

    How do I buy BioTime stock?

    Shares of BioTime can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

    What is BioTime's stock price today?

    One share of BioTime stock can currently be purchased for approximately $2.65.

    How big of a company is BioTime?

    BioTime has a market capitalization of $350.75 million.

    How can I contact BioTime?

    BioTime's mailing address is 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States. The biotechnology company can be reached via phone at +1-510-5213390.

    MarketBeat Community Rating for BioTime (BTX)

    Community Ranking:  2.6 out of 5 (star star)
    Outperform Votes:  84 (Vote Outperform)
    Underperform Votes:  79 (Vote Underperform)
    Total Votes:  163
    MarketBeat's community ratings are surveys of what our community members think about BioTime and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

    Analyst Ratings

    Analysts' Consensus Rating for BioTime (NYSEAMERICAN:BTX)

      (How are Consensus Ratings Calculated?)
    Today30 Days Ago90 Days Ago180 Days Ago
    Consensus Rating: HoldHoldHoldBuy
    Consensus Rating Score: 1.831.502.252.80
    Ratings Breakdown: 2 Sell Rating(s)
    1 Hold Rating(s)
    3 Buy Rating(s)
    0 Strong Buy Rating(s)
    3 Sell Rating(s)
    1 Hold Rating(s)
    2 Buy Rating(s)
    0 Strong Buy Rating(s)
    2 Sell Rating(s)
    2 Hold Rating(s)
    4 Buy Rating(s)
    0 Strong Buy Rating(s)
    0 Sell Rating(s)
    1 Hold Rating(s)
    4 Buy Rating(s)
    0 Strong Buy Rating(s)
    Consensus Price Target: $5.08$5.33$5.33$6.75
    Price Target Upside: 113.59% upside102.02% upside94.65% upside103.93% upside

    Consensus Price Target History for BioTime (NYSEAMERICAN:BTX)

    Price Target History for BioTime (NYSEAMERICAN:BTX)

    Analysts' Ratings History for BioTime (NYSEAMERICAN:BTX)

    DateFirmActionRatingPrice TargetDetails
    6/19/2017Ladenburg Thalmann Financial ServicesReiterated RatingBuy$6.00 -> $6.50View Rating Details
    3/31/2017Raymond James Financial, Inc.Initiated CoverageOutperform -> Outperform$6.00View Rating Details
    4/7/2016Chardan CapitalInitiated CoverageBuyView Rating Details
    4/2/2016Oppenheimer Holdings, Inc.Reiterated RatingBuyView Rating Details
    (Data available from 11/25/2015 forward)


    Earnings History and Estimates Chart for BioTime (NYSEAMERICAN:BTX)

    Earnings by Quarter for BioTime (NYSEAMERICAN:BTX)

    Earnings History by Quarter for BioTime (NYSEAMERICAN BTX)

    DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
    11/3/2016Q316($0.14)($0.08)$1.46 million$1.50 millionViewN/AView Earnings Details
    8/9/2016Q216($0.17)($0.11)$1.75 million$1.27 millionViewN/AView Earnings Details
    5/10/2016Q116($0.14)($0.19)$1.43 million$2.10 millionViewN/AView Earnings Details
    3/15/2016Q4($0.17)($0.16)$1.31 millionViewN/AView Earnings Details
    8/10/2015Q2($0.12)$2.01 millionViewN/AView Earnings Details
    5/11/2015Q115($0.13)$1.10 million$1.30 millionViewN/AView Earnings Details
    11/10/2014Q314($0.12)$1.20 millionViewN/AView Earnings Details
    8/12/2014Q214($0.16)$362.25 million$300.08 millionViewN/AView Earnings Details
    5/12/2014Q114($0.14)$0.61 million$1.07 millionViewN/AView Earnings Details
    11/12/2013Q3($0.16)ViewN/AView Earnings Details
    3/18/2013Q412($0.12)$1.70 million$1.20 millionViewN/AView Earnings Details
    (Data available from 1/1/2011 forward)


    Earnings Estimates for BioTime (NYSEAMERICAN:BTX)
    No earnings estimates for this company have been tracked by


    Dividend History for BioTime (NYSEAMERICAN:BTX)

    No dividend announcements for this company have been tracked by

    Insider Trades

    Insider Trading and Institutional Ownership History for BioTime (NYSEAMERICAN BTX)

    Insider Trades by Quarter for BioTime (NYSEAMERICAN:BTX)
    Insider Trades by Quarter for BioTime (NYSEAMERICAN:BTX)

    Insider Trades by Quarter for BioTime (NYSEAMERICAN BTX)

    Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
    10/13/2017Broadwood Partners, L.P.DirectorBuy2,692,307$2.60$6,999,998.20View SEC Filing  
    8/23/2017Russell SkibstedCFOBuy2,000$2.64$5,280.00View SEC Filing  
    8/22/2017Broadwood Partners, L.P.DirectorBuy10,000$2.60$26,000.00View SEC Filing  
    8/22/2017Michael D. WestCEOBuy2,000$2.60$5,200.00View SEC Filing  
    8/21/2017Aditya P. MohantyCEOBuy7,500$2.50$18,750.00View SEC Filing  
    8/21/2017Deborah J AndrewsDirectorBuy2,396$2.50$5,990.00View SEC Filing  
    7/31/2017Broadwood Partners, L.P.DirectorBuy150,000$2.80$420,000.00View SEC Filing  
    6/16/2017Deborah J AndrewsDirectorBuy2,000$2.95$5,900.00View SEC Filing  
    5/16/2017Deborah J AndrewsDirectorBuy2,000$3.21$6,420.00View SEC Filing  
    2/15/2017Broadwood Partners, L.P.DirectorBuy2,222,222$2.70$5,999,999.40View SEC Filing  
    6/21/2016Broadwood Partners LpDirectorBuy2,732,636$2.39$6,531,000.04View SEC Filing  
    1/20/2016Broadwood Partners LpDirectorBuy300,000$2.35$705,000.00View SEC Filing  
    11/6/2015Alfred D KingsleyInsiderSell100,000$3.83$383,000.00View SEC Filing  
    11/6/2015Stephen C FarrellDirectorBuy50,000$3.83$191,500.00View SEC Filing  
    8/26/2015Deborah J AndrewsDirectorBuy2,000$2.82$5,640.00View SEC Filing  
    8/18/2015Stephen Lahue CarttDirectorBuy75,000$2.80$210,000.00View SEC Filing  
    10/8/2014David SchlachetDirectorBuy32,050$3.12$99,996.00View SEC Filing  
    7/22/2014Broadwood Partners LpDirectorBuy370,000$2.65$980,500.00View SEC Filing  
    7/22/2014Michael D WestCEOSell270,000$2.65$715,500.00View SEC Filing  
    7/22/2014Robert PeabodyCFOSell100,000$2.65$265,000.00View SEC Filing  
    6/17/2014William P Phd TewInsiderSell30,000$3.07$92,100.00View SEC Filing  
    6/16/2014Broadwood Partners LpDirectorBuy1,000,000$2.50$2,500,000.00View SEC Filing  
    5/16/2014Broadwood Partners LpDirectorBuy300,000$2.45$735,000.00View SEC Filing  
    5/8/2014Broadwood Partners LpDirectorBuy300,000$2.44$732,000.00View SEC Filing  
    5/1/2014Broadwood Partners LpDirectorBuy2,000,000$2.52$5,040,000.00View SEC Filing  
    2/25/2014Broadwood Partners LpDirectorBuy500,000$3.74$1,870,000.00View SEC Filing  
    12/30/2013Neal C BradsherDirectorBuy300,042$3.51$1,053,147.42View SEC Filing  
    11/20/2013William P Phd TewInsiderSell13,860$3.76$52,113.60View SEC Filing  
    9/12/2013Stephen C FarrellDirectorBuy11,213$3.89$43,618.57View SEC Filing  
    8/20/2013Stephen C FarrellDirectorBuy4,187$3.65$15,282.55View SEC Filing  
    8/12/2013Eschenbach Andrew C VonDirectorBuy3,000$3.69$11,070.00View SEC Filing  
    3/28/2013Broadwood Partners LpDirectorBuy200,000$3.81$762,000.00View SEC Filing  
    11/15/2012Broadwood Partners LpDirectorBuy344,828$2.90$1,000,001.20View SEC Filing  
    (Data available from 1/1/2013 forward)


    Latest Headlines for BioTime (NYSEAMERICAN BTX)

    BioTime (BTX) Announces Updated OpRegen® Phase I/IIa Trial Data - StreetInsider.comBioTime (BTX) Announces Updated OpRegen® Phase I/IIa Trial Data - - November 16 at 10:13 PM
    BioTime, Inc.: Trading close to its 50 day moving average. Good buy?BioTime, Inc.: Trading close to its 50 day moving average. Good buy? - November 16 at 12:14 PM
    BioTime, Inc. (BTX) Lifted to Buy at Zacks Investment ResearchBioTime, Inc. (BTX) Lifted to Buy at Zacks Investment Research - November 15 at 5:06 PM

    Social Media



    BioTime (NYSEAMERICAN BTX) Chart for Saturday, November, 25, 2017
    Loading chart…

    This page was last updated on 11/25/2017 by Staff

    Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.